Reply to Zhou and Tsao: Synergy rarely underlies the benefits of combination cancer therapy
Proceedings of the National Academy of Sciences · 10.11.2026 · 123 (45)
DOI: 10.1073/pnas.2618841123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 30.10.2026. Verfasst von Nicole A Traphagen Ho und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | NCI | Center for Cancer Research (CCR).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215.
ORCID-Profile: Myles Brown
Förderung
- NCI NIH HHS
- HHS | NIH | NCI | Center for Cancer Research (CCR)
Zitieren
APA
Traphagen Ho, N. A., & Brown, M. (2026). Reply to Zhou and Tsao: Synergy rarely underlies the benefits of combination cancer therapy. Proceedings of the National Academy of Sciences, 123(45). https://doi.org/10.1073/pnas.2618841123
Vancouver
Traphagen Ho NA, Brown M. Reply to Zhou and Tsao: Synergy rarely underlies the benefits of combination cancer therapy. Proceedings of the National Academy of Sciences. 2026;123(45). doi:10.1073/pnas.2618841123
BibTeX
@article{TraphagenHo2026,
author = {Traphagen Ho, Nicole A and Brown, Myles},
title = {Reply to Zhou and Tsao: Synergy rarely underlies the benefits of combination cancer therapy},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {45},
doi = {10.1073/pnas.2618841123}
}
EUVIMED